1R44CA233143-01 (R44) ApplID: 9622376 | |||
---|---|---|---|
Title | Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy | ||
Institution | B-MOGEN BIOTECHNOLOGIES, INC., Minneapolis, MN | ||
Principal Investigator | LAMPI HERMANSON, DAVID | NCI Program Director | Hallett |
Cancer Activity | Small Business - Cancer Biology | Division | SBIRDC |
Funded Amount | $218,588 | Project Dates | 08/06/2018 - 02/05/2019 |
Fiscal Year | 2018 | Project Type | Grant |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Childhood Cancers (50.0%) Gene Therapy (100.0%) |
Childhood Leukemia (50.0%) | ||
Research Type | |||
Systemic Therapies - Discovery and Development | |||
Abstract | |||
- |